Back to Search
LEIGH KWAK, M.D.
M.D.
Endocrinology, Diabetes & Metabolism Physician
NPI: 1548614977IndividualAccepts Medicare
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
311983(NY)
Education
OTHER
Class of 2016
Research & Publications (20)
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
PMID 19150940·Ann Oncol·2009
8-other
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.
PMID 19188166·Clin Cancer Res·2009
7-preclinical
Associations between physical activity, fitness, and academic achievement.
PMID 19643438·J Pediatr·2009
8-other
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
PMID 19423729·Blood·2009
7-preclinical
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
PMID 19654406·Blood·2009
7-preclinical
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
PMID 18922919·Cancer Res·2008
7-preclinical
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
PMID 18381957·Clin Cancer Res·2008
7-preclinical
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
PMID 18411419·Blood·2008
3-trial
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
PMID 18615506·Cancer·2008
4-observational
Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells.
PMID 18813280·Mol Ther·2008
7-preclinical
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
PMID 18973182·Cancer·2008
3-trial
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
PMID 18764869·Br J Haematol·2008
3-trial
Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
PMID 17722077·Am J Hematol·2008
6-review
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
PMID 18083690·Ann Oncol·2008
8-other
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
PMID 17898787·Leukemia·2008
7-preclinical
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones.
PMID 17959194·J Immunol Methods·2008
8-other
Vaccine therapy for B-cell lymphomas: next-generation strategies.
PMID 18024636·Hematology Am Soc Hematol Educ Program·2007
6-review
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.
PMID 17785206·Cancer Cell·2007
7-preclinical
Elevated serum BLyS levels in patients with non-Hodgkin lymphoma.
PMID 17786728·Leuk Lymphoma·2007
8-other
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.
PMID 17933439·Vaccine·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 41 E POST RD
WHITE PLAINS, NY 10601 - Phone
- (914) 681-0600
Quick Facts
- NPI
- 1548614977
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 10
- Publications
- 20
Are you this provider?
Claim Your Profile